Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab combined with IMRT for nasopharyngeal carcinoma after inadequate induction chemotherapy response
ChiCTR2100042602Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Feb 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100042602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042602.